Your Article Summary
See Latest ArticlesMonitoring Cholesterol Levels: Measurement Error or True Change
Annals of Internal Medicine, 05/09/08
Glasziou P et al. - This analysis of data from a trial that compared pravastatin with placebo in patients with coronary disease found that the signal–noise ratio in cholesterol monitoring was weak. Consider testing adherent patients with well-controlled cholesterol levels every 3 to 5 years rather than every few months or annually.
Related Articles
Pravastatin and cardiovascular risk in moderate chronic kidney disease
Atherosclerosis, 10/07/09
Relevance Score: 88%
Pravastatin use and cancer risk: a meta-analysis of individual patient data from long-term prospective controlled trials in Japan
Pharmacoepidemiology and Drug Safety, 10/27/09
Relevance Score: 87%
11C-meta-hydroxyephedrine defects persist despite functional improvement in hibernating myocardium
Journal of Nuclear Cardiology, 11/18/09
Relevance Score: 80%
Review: statins do not protect against development of dementia
Evidence-Based Mental Health, 10/30/09
Relevance Score: 80%
Today in Cardiology...keeping you current
Receive free subspecialty "5-minute updates" via email
How do providers assess antihypertensive medication adherence in medical encounters?
Journal of General Internal Medicine, 12/18/09
Gestational diabetes mellitus: an opportunity to prevent Type 2 diabetes and cardiovascular disease in young women
Women's Health, 12/18/09
Influence of sex hormones and phytoestrogens on heart disease in men and women
Women's Health, 12/18/09